Local and systemic safety and tolerability of ascending doses of TOP-N53, a nitric oxide (NO)-releasing phosphodiesterase-5 (PDE5) inhibitor, administered topically, on wound in patients with
digital ulcers (DU) in systemic sclerosis (SSc) in an open-label, vehicle-controlled, phase 2a, multi-center clinical trial
RecruitingCTIS2024-511861-12-00
Topadur Pharma Deutschland GmbH, Topadur Pharma AGDigital ulcers in systemic sclerosis
Start: 2025-02-04Target: 8Updated: 2026-01-20